Nature

First-line treatment for CLL in the era of targeted therapy

In the decade since FDA approval of the first-generation Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, the treatment landscape for chronic lymphocytic leukemia (CLL) has transformed. Targeted ...
Nature

Defining the acute BTK-loss transcriptional program in CLL using a BTK degrader

Constitutive activation of the B-cell receptor (BCR) signaling pathway is a hallmark of chronic lymphocytic leukemia (CLL), driving the malignant cell survival, proliferation, and interaction with the ...
The American Journal of Managed Care

Clonal Hematopoiesis Is Quietly Reshaping CLL Treatment

Error-corrected sequencing of non–B-cell fractions in CLL12/CLL14 detected CH in ~58% of CLL, with 35% meeting CHIP criteria. Cytotoxic regimens, especially chlorambucil-based therapy, were linked to ...
ascopubs.org

Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor–Based ...

This is a retrospective observational study using Optum Clinformatics Data Mart of adult patients with CLL/small lymphocytic lymphoma who received 2L venetoclax- or BTKi-based regimens (January ...